Objective To explore the clinical efficacy and safety of pegylated interferon α-2a combination with Ribavirin in treatment of hepatitis C and cirrhosis patients. Methods 62 cases of patients with hepatitis C and cirrhosis were randomly divided into two groups. The control group received conventional treatment, research group withpeginterferon α-2a and ribavirin treatment, to evaluate the clinical efficacy and adverse reactions of the two groups. Results The TBi L, ALT, AST of liver function was not statistically significant in two group before treatment（P〉0.05）, but after treatment, this indicators were significantly decreased than treatment before（P〈0.05）, and the decline in the study group was significantly higher than the control group（P〈0.05）. Conclusion Pegylated interferon α-2a combination with Ribavirin treatment of hepatitis C and cirrhosis patients has exact effect and antifibrosis.
China Continuing Medical Education